Form 8-K - Current report:
SEC Accession No. 0001599298-25-000099
Filing Date
2025-05-30
Accepted
2025-05-30 16:17:49
Documents
19
Period of Report
2025-05-30
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K smmt-20250530.htm   iXBRL 8-K 29604
2 EX-99.1 a2025_prx0530-xxharmonix.htm EX-99.1 18465
7 a2025_prx0530-xxharmonix001.jpg GRAPHIC 274507
8 a2025_prx0530-xxharmonix002.jpg GRAPHIC 267783
9 a2025_prx0530-xxharmonix003.jpg GRAPHIC 259300
10 a2025_prx0530-xxharmonix004.jpg GRAPHIC 247273
11 a2025_prx0530-xxharmonix005.jpg GRAPHIC 156951
  Complete submission text file 0001599298-25-000099.txt   1862726

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT smmt-20250530.xsd EX-101.SCH 2042
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT smmt-20250530_def.xml EX-101.DEF 14787
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT smmt-20250530_lab.xml EX-101.LAB 26043
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT smmt-20250530_pre.xml EX-101.PRE 15429
21 EXTRACTED XBRL INSTANCE DOCUMENT smmt-20250530_htm.xml XML 2735
Mailing Address 601 BRICKELL KEY DRIVE SUITE 1000 MIAMI FL 33131
Business Address 601 BRICKELL KEY DRIVE SUITE 1000 MIAMI FL 33131 305-203-2034
Summit Therapeutics Inc. (Filer) CIK: 0001599298 (see all company filings)

EIN.: 371979717 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36866 | Film No.: 251011198
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)